Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03244280 · ClinicalTrials.gov registry record · Phase 1
A Study of the Systemic Absorption of MOB015B
A Phase 1 study, sponsored by Moberg Pharma AB.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT03244280 is a Phase 1 study that has completed, run by Moberg Pharma AB. The registered enrollment target is 20 participants.
The verdict
NCT03244280, a Phase 1 study, has completed, sponsored by Moberg Pharma AB.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
A Study of the Systemic Absorption of Once Daily MOB015B when Applied for 28 Days in Subjects with Moderate to Severe Onychomycosis of the Toenails.
Interventions
- DRUG MOB015B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-12-16 |
| Est. Completion | 2018-04-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03244280
The ClinicalTrials.gov registry entry for NCT03244280 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Moberg Pharma AB, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MOB015B is the first listed.
NCT03244280 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03244280 about?
NCT03244280 is a clinical study titled "A Study of the Systemic Absorption of MOB015B". A Study of the Systemic Absorption of Once Daily MOB015B when Applied for 28 Days in Subjects with Moderate to Severe Onychomycosis of the Toenails.
What is the current status of trial NCT03244280?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2017-12-16. Estimated completion is 2018-04-23.
What interventions are being tested in trial NCT03244280?
The interventions under investigation include: MOB015B (DRUG).
Who is sponsoring clinical trial NCT03244280?
This trial is sponsored by Moberg Pharma AB, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.